# Sharda Cropchem share price today (Sharda Cropchem Ltd, NSE: SHARDACROP) > Sharda Cropchem share price today: ₹698.75 at the NSE close on 18 November 2026, down 12.6% in a year. Sharda Cropchem (NSE: SHARDACROP) is worth ₹6,309 crore, trades at a P/E of 9.8 and has closed between ₹642.60 and ₹1,256.00 over the past 52 weeks. > Sharda Cropchem Ltd's earnings have grown faster than its share price. Earnings per share grew +123.7% in a year while the price moved −12.6%. SHARDACROP · Pesticides/Agrochemicals · data as of 18 November 2026. Page: https://www.sectoralpha.in/stocks/sharda-cropchem-ltd Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms ## Key numbers - Business trend: Mixed, from the last 12 quarters - Price: ₹698.75 (−12.6% in a year) - P/E: 9.8× (lower than 98% of the last 11 years) - Revenue (Sep 2026): ₹1,052 Cr (+13.2% on a year ago) - Profit (Sep 2026): ₹92.0 Cr (+24.3% on a year ago) - Operating margin: 15.6% (+1.3 points on a year ago) - ROCE: 30%, FY26 - ROIC: 23.5%, against a 12.0% cost of capital: +11.5 points The main question: yearly earnings per share moved +123.7% while the share price moved −12.6%. ## What is the Sharda Cropchem share price today? Sharda Cropchem Ltd's share price was ₹698.75 at the close on 18 November 2026. It has been falling for 18 weeks. That is 15.5% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹643 and ₹1,256, and at that close it sat 9% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 35 weeks running. Over the last 11 years the share price moved +236% while the NIFTY 500 moved +306%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 30 April 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Sharda Cropchem this quarter? 1. Revenue up on a year earlier for 10 quarters in a row In the September 2026 quarter revenue was ₹1,052 crore, +13.2% on a year earlier. Why: Revenue rose because higher prices and currency moves, plus a better mix of products sold, more than made up for lower volumes. Next results: check whether overall volumes return to growth. From the earnings call on 2 Nov 2026. ## What are Sharda Cropchem's latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Sharda Cropchem reported revenue of ₹1,052 crore, up 13.2% from ₹929 crore a year earlier, and a profit of ₹92.0 crore, up 24.3% from ₹74.0 crore. ### Sharda Cropchem results: July to September 2026 against a year earlier | Measure | July to September 2026 | July to September 2025 | Change | | --- | --- | --- | --- | | Revenue | ₹1,052 crore | ₹929 crore | +13.2% | | Profit | ₹92.0 crore | ₹74.0 crore | +24.3% | | Earnings per share | ₹10.17 | ₹8.24 | +23.4% | | Operating margin | 15.6% | 14.3% | +1.3 points | The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Sharda Cropchem's management discussed these results on a call held on 2 November 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.) ## What is the Sharda Cropchem share price history? Sharda Cropchem closed at ₹698.75 on 18 November 2026, down 12.6% from ₹799.35 a year earlier (21 November 2025) and up 108.7% over five years. Its highest weekly close since February 2016 was ₹1,256.00 on 13 February 2026. ### Sharda Cropchem share price: then and now | When | Close | Change to 18 Nov 2026 | | --- | --- | --- | | 1 week ago · 11 Nov 2026 | ₹715.70 | −2.4% | | 1 month ago · 19 Oct 2026 | ₹699.80 | −0.2% | | 6 months ago · 15 May 2026 | ₹969.00 | −27.9% | | 1 year ago · 21 Nov 2025 | ₹799.35 | −12.6% | | 3 years ago · 17 Nov 2023 | ₹426.30 | +63.9% | | 5 years ago · 18 Nov 2021 | ₹334.85 | +108.7% | | 10 years ago · 18 Nov 2016 | ₹391.60 | +78.4% | | Earliest weekly close in our records · 26 Feb 2016 | ₹208.25 | +235.5% | | Highest weekly close since February 2016, also the 52-week high · 13 Feb 2026 | ₹1,256.00 | −44.4% | | Lowest weekly close since February 2016 · 3 Apr 2020 | ₹105.05 | +565.2% | | 52-week low (weekly close) · 23 Oct 2026 | ₹642.60 | +8.7% | Weekly closing prices. Each change is the move from that price to the 18 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (567 weekly closes from 26 February 2016 to 18 November 2026.) ## What is the latest news on Sharda Cropchem? 18 Nov 2026: Sharda Cropchem closed at ₹698.75, down 2.4% on the week and down 0.2% on the month. 2 Nov 2026: Sharda Cropchem held its results call for July to September 2026. Management guided: FY27 revenue growth 10-15%. ### Earlier - Results for July to September 2026: Revenue up 13.2% and profit up 24.3% on a year earlier. - 7 Aug 2026: ex-date for a dividend of ₹9 a share. - 6 Feb 2026: ex-date for an interim dividend of ₹6 a share. ## What dividend does Sharda Cropchem pay? Sharda Cropchem paid ₹15 a share in regular dividends in the 12 months to 18 November 2026 (2 payments), a yield of 2.15% at the ₹698.75 close on 18 November 2026. The last was a dividend of ₹9 a share, ex-date 7 August 2026. ### Sharda Cropchem dividends since 1 April 2021 | Ex-date | Dividend per share | Type | Record date | | --- | --- | --- | --- | | 7 Aug 2026 | ₹9 | Dividend | same day | | 6 Feb 2026 | ₹6 | Interim | same day | | 7 Aug 2025 | ₹6 | Dividend | same day | | 6 Feb 2025 | ₹3 | Interim | same day | | 2 Aug 2024 | ₹3 | Dividend | same day | | 1 Aug 2023 | ₹3 | Dividend | same day | | 7 Feb 2023 | ₹3 | Interim | same day | | 25 Jul 2022 | ₹3 | Dividend | 26 Jul 2022 | | 2 Feb 2022 | ₹3 | Interim | 3 Feb 2022 | | 20 Jul 2021 | ₹3 | Dividend | 22 Jul 2021 | Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 5 of 5 Of the last 5 financial years, years with an NSE dividend record Yes. Sharda Cropchem Ltd paid out 20% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years. (From the NSE corporate-actions record, read 18 November 2026.) ## What did Sharda Cropchem management say on the latest results call? On the call for July to September 2026, held on 2 November 2026, Sharda Cropchem's management guided: FY27 revenue growth 10-15%. > “We see this as a temporary, weather-led impact rather than any change in underlying demand.” > R. V. Bubna, on the call for July to September 2026 ### What management guided - FY27 operating margin 18-20% on better mix and operating leverage in second half. - FY27 registration capital spending ₹550-600 crore backed by strong pipeline. - Second-half operating margin above 20% to reach full-year low end. - Europe to do well in seasonally stronger second half as conditions normalize. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/7085/Conference Call/CC-Nov26.pdf). (From the call for July to September 2026, 2 November 2026.) ## What to watch in Sharda Cropchem's next results? When Sharda Cropchem reports October to December 2026, these are the 2 checks that show whether the story is still on course. First: Volume turn from price and mix-led growth - verify volume returns to growth and pricing improvement pace accelerates. Management raised each of these on the latest results call. - Volume turn from price and mix-led growth - verify volume returns to growth and pricing improvement pace accelerates. - Registration spend discipline after arbitration overshoot - track quarterly spend against raised plan and pipeline conversion progress. ## Which stock lists is Sharda Cropchem on? Sharda Cropchem is on one of our India lists: Dividend stocks. [Dividend stocks Regular dividend yield (%): 2.1](https://www.sectoralpha.in/dividend-stocks-india) ## Is Sharda Cropchem profitable? Sharda Cropchem Ltd earned ₹92.0 Cr of net profit in the Sep 2026 quarter, +24.3% on the same quarter a year earlier. Full-year FY26 profit was ₹681 Cr. Over 10 years profit has grown 14.6% a year on average. The Sep 2026 quarter's profit is 8.7% of that quarter's revenue. The same quarter a year earlier earned ₹74.0 Cr. For the full year, FY26 profit was ₹681 Cr (+124.0% on the year before). Why profit moved: revenue changed +13.2% on a year earlier and the margin moved +1.3 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +102.5% and revenue +18.5%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Sharda Cropchem make, and is it growing? Sharda Cropchem Ltd reported ₹1,052 Cr of revenue in the Sep 2026 quarter, +13.2% on the same quarter a year earlier. That is the 10th quarter in a row with growth on the year before. Over 10 years it has grown 15.7% a year on average. The last full year, FY26, came in at ₹5,268 Cr. Why this happened. Europe accounts for ~45% of agrochemical sales and has the highest regional margin (42.5% gross margin in FY26 vs NAFTA 28%, LATAM 29%, Rest of World 37%). FY26 Europe volume grew ~16%. The EUR-USD cross-currency benefit added 10-11% to revenue growth, EUR was 1.04-1.03 vs USD a year ago vs 1.17 in FY26. Management guided similar Europe volume growth in FY27. NAFTA declined 6% in Q4 due to weather/US economic conditions, cited as non-structural. The last four reported quarters add to ₹5,480 Cr. FY26 revenue was ₹5,268 Cr, +21.9% on the year before. Recent pace: the last four quarters grew +18.5% on average, against 15.7% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +17.3%, against +25.0% a year over the last 8 quarters (rolling over); profit over the last 12 months grew +42.5%, against +72.3% a year (rolling over). ## How much of every ₹100 of sales does Sharda Cropchem keep? Sharda Cropchem Ltd's operating margin was 15.6% in the Sep 2026 quarter, 1.3 percentage points higher than the same quarter a year ago. Across 13 years it has been between 9.6% and 23.2%. The latest quarter is within that range. Why this happened. Sharda's registration portfolio is the central competitive asset. As of March 31, 2026, the company has 3,011 product registrations across 70-75 countries (up from 2,994 as of Sep 2025 and 3,004 as of Dec 2025). The pipeline of 1,400 applications globally is the forward conversion funnel. Each registration approved creates a new revenue channel with pricing power from limited competition. Europe has 1,675 of the total (56% of registrations) with the highest gross margin at 42.5% in FY26. Management noted registrations process is highly uncertain (1-7 years) and FY27 growth does not solely depend on new molecule volumes. Why the margin moved: operating margin changed +1.3 percentage points on the year while gross margin changed +1.4 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Sharda Cropchem's profit turning into cash? Over the last 3 years, 157% of Sharda Cropchem Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹656 Cr of operating cash against ₹681 Cr of profit. After ₹1.0 Cr of spending on assets, ₹655 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 157% of profit came in as cash: the cash cycle got 11 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets. ## Where does Sharda Cropchem's cash go? Sharda Cropchem Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 125 days in FY26, up from 114 days in FY21. It spent ₹1.0 Cr on assets over the last 3 years. Customers take 166 days to pay, and stock sits for 121 days on average. At FY26 sales of ₹5,268 Cr, each day of that cycle ties up about ₹14.4 Cr, so roughly ₹1,804 Cr is tied up in the business at any time. FY26: customers took 166 days to pay and stock sat for 121 days, about 4.0 months of sales sitting as stock, for a full cycle of 125 days, longer than FY21's 114. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 121 days. Customers pay about 166 days after that. Suppliers are paid at 162 days. Together that makes the 125-day cycle. Spending on assets: ₹1.0 Cr over the last 3 years, against ₹867 Cr of depreciation (the yearly wear and tear on existing assets). So it is spending about what it takes to replace what wears out, or less. Work still in progress is ₹247 Cr (FY26): assets paid for that are not earning yet. In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean. ## What is Sharda Cropchem's P/E ratio, and how does it compare with its own history? Sharda Cropchem Ltd's P/E is 9.8×, about the lowest it has ever been. Its usual P/E (the middle reading) is 16.8×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +123.7% while the price moved −12.6%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved +15.8% a year; about +20.7% a year came from earnings growth and about −4.9 percentage points from the multiple (the market paying less); over 10 years the price moved +6.0% a year; about +13.3% a year came from earnings growth and about −7.3 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Sharda Cropchem business getting better or worse? Sharda Cropchem Ltd's business is giving mixed signals. Growth is slowing from a very fast pace: profit growth has eased from +185.7% at its peak to +42.5%, but the business is still expanding, with ROCE rising at 25.9% (four quarters to Sep 2026). This is based on 12 quarters of 4 measures. Why it matters: when the lines disagree, each line above matters more than any single label. ## What is the Sharda Cropchem story, and has it been checked? Sharda Cropchem Ltd's story is not scored yet against the checks our research set on 17 May 2026. Where it sits in its own cycle: post peak earnings. Our read, 17 May 2026. Best-ever year in company history followed by a cautious guide-down, the margin story is real, but guidance credibility has a fresh crack. From the numbers. The compression (-53%) is entirely earnings-driven: EPS tripled as earnings recovered from FY24 trough (Rs 3.53 EPS) to FY26… From the price. Price stage 4, week 18, below its 200-day line, relative strength falling. Where they disagree. The compression (-53%) is entirely earnings-driven: EPS tripled as earnings recovered from FY24 trough (Rs 3.53 EPS) to FY26 record (~Rs 75 EPS annualized). What is not proven yet. The test written in advance. FY27 Revenue Guidance Step-Down Without Explanation. Measured by: FY27 Revenue Guidance Step-Down Without Explanation Q1 FY27 revenue print vs 10-15% annualized pace by the next result. The test written in advance. EUR/USD Reversal Compresses Reported Margins. Measured by: EUR/USD Reversal Compresses Reported Margins EUR/USD rate + Q1 FY27 reported gross margin vs 35% band by the next result. The test written in advance. NAFTA Structural Weakness vs Weather Narrative. Measured by: NAFTA Structural Weakness vs Weather Narrative Q1 FY27 NAFTA revenue trend + management tone by the next result. What the company does. FY26 delivered best-ever revenue (Rs 5,268 Cr, +22% YoY), EBITDA (Rs 1,040 Cr, 19.7% margin, +69% YoY), and PAT (Rs 681 Cr, +124% YoY), a historic milestone off a deeply depressed FY24 base. The 3,011-registration moat + 1,400-application pipeline + 80-90% raw material pass-through pricing power underpin structural margin sustainability at 35% gross / 18-20% EBITDA for FY27. Management guided FY27 revenue only 10-15% (down from 15-20% Q3 commentary and well below FY26 actuals of 22%) without adequate explanation, creates material ambiguity and a guidance credibility watch. Lever 2 · Value-added mix: building. 3,011 total registrations + 1,400 pipeline applications, the moat expands every quarter as approvals convert, enabling volume growth in new molecules and markets. What proves it keeps working: Registration Moat + Pipeline Execution. It stops working if Q1 FY27 revenue print vs 10-15% annualized pace. Lever 10 · New geographies: building. Europe drove FY26 agrochemical segment to +25% revenue with 16% volume growth and 42.5% gross margin, the single most important profit driver in the portfolio. What proves it keeps working: Europe Volume Growth + EUR/USD Tailwind. Lever 1 · Operating leverage: building. 80-90% raw material pass-through capability due to limited competition from registration barriers, structural margin protection that separates Sharda from commodity agchem players. What proves it keeps working: Pricing Power + Raw Material Pass-Through. Lever 14 · A bigger market to serve: building. Post-COVID inventory destocking fully normalized; global agrochemical demand revival after 18-24 months of channel correction, provides volume floor across all regions. What proves it keeps working: Global Market Recovery + Inventory Normalization. Sources: our stock research file (17 May 2026) · quarterly results through Sep 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes. ## Did Sharda Cropchem management deliver what it promised? What Sharda Cropchem Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met. Europe Restocking Outlook Reversed · 2 November 2026. In Jul 2026, management described European distributor restocking as normalized and expected volume recovery in coming quarters. In Nov 2026, management said the weather-driven restocking problem had continued through September and distributors were still cautious. Although the latest call attributes this to extended heat and drought, it does not reconcile the reversal from the earlier normalization assessment. Capex Assumption Changed Despite Prior No-Repeat Assurance · 2 November 2026. In Jul 2026, management said FY27 capex had not been revised and characterized the heavy Q1 data-compensation spending as non-recurring. In Nov 2026, management presented planned capex of Rs.550 to Rs.600 crores and reported Rs.419 crores spent in H1, while again citing unexpectedly high registration spending. The latest arbitration explanation is plausible, but management did not reconcile it with the prior statement that the exceptional spending would not repeat, creating a material cash deployment uncertainty. FY27 Volume Growth Outlook Reduced · 30 July 2026. In May 2026, management indicated that FY27 volume growth should be around 15%. In the latest call in Jul 2026, management reduced the expected range to 5-10% without explaining the change, a material reduction that could affect the revenue growth outlook and operating assumptions. FY26 EBITDA Margin Delivery Materially Exceeded Both Prior Guidance Ranges Without Explanation · 14 May 2026. Both prior calls consistently guided FY26 EBITDA margins at 15% to 18%, with the Oct 2025 call affirming management was on track for this range even after H1 FY26 delivered only 14.7% EBITDA margins. The Latest Call (May 2026) reports actual FY26 EBITDA margins of 19.7% - approximately 170 basis points above the top of the guided range - with Q4 FY26 alone reaching 24.8%. No explanation is offered for this material outperformance relative to guidance maintained consistently through two consecutive calls, and FY27 EBITDA guidance is now set at 18-20%, which remains below both the FY26 actual of 19.7% and the recent Q4 run rate of 24.8%, raising questions about guidance credibility. Every quote above is taken word for word from the company’s own earnings calls. ## How much does Sharda Cropchem earn on its capital? Sharda Cropchem Ltd earned a ROCE of 30% in FY26. That is up from a low of 4% in FY24. Its return on capital used (ROIC) is 11.5 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 12.9% net margin and 0.92× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 12.9% net margin × 0.92× asset turnover × 1.84× leverage (assets divided by equity) ≈ 21.8% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 23.5% − 12.0% = +11.5 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value. The 23.5% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 27.1%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Sharda Cropchem have too much debt? Sharda Cropchem Ltd has total debt of ₹24.0 Cr against shareholder equity of ₹3,250 Cr as of Sep 2026, so its debt is 0.01× its equity, which is very little. Year by year, that ratio went from 0.03 in FY22 to 0.00 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Sharda Cropchem shareholding pattern? Domestic institutions cut their stake in Sharda Cropchem Ltd by 3.5 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 9.2% of the company. Foreign institutions moved +0.8 points over the same period, to 3.3%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Domestic institutions: −3.5 points over 8 quarters, to 9.2%; Foreign institutions: +0.8 points over 8 quarters, to 3.3%; Promoters: +0.0 points over 8 quarters, to 74.8%. Why the owners changed: domestic institutions drove it (−3.5 points), with the other side taken by foreign institutions (+0.8 points). They reduced their stake. ## How far is Sharda Cropchem from balance-sheet trouble? For Sharda Cropchem Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Sharda Cropchem rank in its industry? 66.9 out of 100, rank 2 of 25 in Pesticides/Agrochemicals, with 100% of the evidence available. Sharda Cropchem Ltd scores 66.9 out of 100 against the 25 companies it is compared with in Pesticides/Agrochemicals, ranking 2. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 28.2 + 19.6 + 11.5 + 7.6 = 66.9. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Sharda Cropchem compared with? Sharda Cropchem ranks 2 of 25 Pesticides/Agrochemicals companies on the 4-Factor Sector Score, with 66.9 out of 100. 1. [Titan Biotech Ltd](https://www.sectoralpha.in/stocks/titan-biotech-ltd) breaking out · Most evidence points up · 87% evidence 76.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.3/35 · Revenue 31.8% · Profit 38.7% · Operating margin change 3 points · 95% evidence Capital efficiency 21.3/25 · ROCE 22.8% (year to Mar 2026) · Operating margin 19.7% · 95% evidence Valuation 5.4/20 · P/E 55.2× · PEG n/a · 50% evidence Relative strength 18.6/20 · Strength vs its industry (price vs its 52-week average, weekly) 44.3% · Strength vs NIFTY 500 (same reading) 21.3% · 1 year 177.2% · 100% evidence · 4 of 12 weeks ahead Exact sum: 31.3 + 21.3 + 5.4 + 18.6 = 76.6 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. Sharda Cropchem Ltd this page SHARDACROP · basing · Most evidence points up · 100% evidence 66.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.2/35 · Revenue 17.3% · Profit 42.5% · Operating margin change 2 points · 100% evidence Capital efficiency 19.6/25 · ROCE 30.2% (year to Mar 2026) · Operating margin 15.6% · 100% evidence Valuation 11.5/20 · P/E 9.8× · PEG 2.28 · 100% evidence Relative strength 7.6/20 · Strength vs its industry (price vs its 52-week average, weekly) -5.2% · Strength vs NIFTY 500 (same reading) -21.1% · 1 year -12.6% · 100% evidence · 0 of 12 weeks ahead Exact sum: 28.2 + 19.6 + 11.5 + 7.6 = 66.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Jubilant Ingrevia Ltd](https://www.sectoralpha.in/stocks/jubilant-ingrevia-ltd) JUBLINGREA · quiet · Most evidence points up · 93% evidence 65.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.4/35 · Revenue 15.4% · Profit 21.9% · Operating margin change 3 points · 100% evidence Capital efficiency 13.8/25 · ROCE 11.4% (year to Mar 2026) · Operating margin 15.2% · 100% evidence Valuation 12.9/20 · P/E 26.7× · PEG 1.16 · 65% evidence Relative strength 11.2/20 · Strength vs its industry (price vs its 52-week average, weekly) 3.8% · Strength vs NIFTY 500 (same reading) -13.5% · 1 year -18.5% · 100% evidence · 2 of 12 weeks ahead Exact sum: 27.4 + 13.8 + 12.9 + 11.2 = 65.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Bayer CropScience Ltd](https://www.sectoralpha.in/stocks/bayer-cropscience-ltd) BAYERCROP · quiet · Evidence leans up · 85% evidence 63.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.5/35 · Revenue -5% · Profit 22.5% · Operating margin change 4 points · 100% evidence Capital efficiency 19.3/25 · ROCE 29.1% (year to Mar 2026) · Operating margin 17.4% · 100% evidence Valuation 10.6/20 · P/E 20.2× · PEG 2.21 · 100% evidence Relative strength 8.6/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) -22.1% · 1 year -26.2% · 25% evidence · 0 of 12 weeks ahead Exact sum: 24.5 + 19.3 + 10.6 + 8.6 = 63 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Dhanuka Agritech Ltd](https://www.sectoralpha.in/stocks/dhanuka-agritech-ltd) DHANUKA · quiet · Evidence leans up · 100% evidence 54.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 10.0/35 · Revenue 0% · Profit 0.7% · Operating margin change 0 points · 100% evidence Capital efficiency 19.8/25 · ROCE 25.9% (year to Mar 2026) · Operating margin 23.3% · 100% evidence Valuation 11.4/20 · P/E 14.8× · PEG 2.07 · 100% evidence Relative strength 13.5/20 · Strength vs its industry (price vs its 52-week average, weekly) 0.8% · Strength vs NIFTY 500 (same reading) -16.1% · 1 year -23.7% · 100% evidence · 0 of 12 weeks ahead Exact sum: 10 + 19.8 + 11.4 + 13.5 = 54.7 · What this means: Relative strength against the index is -16.1%, and revenue and profit growth are weak. 6. [Advance Agrolife Ltd](https://www.sectoralpha.in/stocks/advance-agrolife-ltd) ADVANCE · losing its lead · Evidence leans up · 68% evidence 54.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.0/35 · Revenue 49.4% · Profit 55.2% · Operating margin change -4 points · 100% evidence Capital efficiency 13.7/25 · ROCE 19.6% (year to Mar 2026) · Operating margin 7.7% · 100% evidence Valuation 10.1/20 · P/E 17.4× · PEG n/a · 15% evidence Relative strength 11.9/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 2.3% · 1 year -8.5% · 25% evidence · 10 of 12 weeks ahead Exact sum: 19 + 13.7 + 10.1 + 11.9 = 54.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Punjab Chemicals & Crop Protection Ltd](https://www.sectoralpha.in/stocks/punjab-chemicals-crop-protection-ltd) PUNJABCHEM · quiet · Evidence leans up · 75% evidence 53.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.6/35 · Revenue 14% · Profit 13.2% · Operating margin change -1 points · 100% evidence Capital efficiency 13.2/25 · ROCE 18.6% (year to Mar 2026) · Operating margin 9.2% · 100% evidence Valuation 11.0/20 · P/E 17.9× · PEG n/a · 50% evidence Relative strength 9.2/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) -19% · 1 year -34.1% · 25% evidence · 3 of 12 weeks ahead Exact sum: 19.6 + 13.2 + 11 + 9.2 = 53 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Dharmaj Crop Guard Ltd](https://www.sectoralpha.in/stocks/dharmaj-crop-guard-ltd) DHARMAJ · quiet · Evidence leans up · 75% evidence 52.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.5/35 · Revenue 3.8% · Profit 14.3% · Operating margin change -2 points · 100% evidence Capital efficiency 14.7/25 · ROCE 16.8% (year to Mar 2026) · Operating margin 7.2% · 100% evidence Valuation 13.2/20 · P/E 15.1× · PEG n/a · 50% evidence Relative strength 10.0/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) -9.7% · 1 year -0.9% · 25% evidence · 5 of 12 weeks ahead Exact sum: 14.5 + 14.7 + 13.2 + 10 = 52.4 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 9. [Best Agrolife Ltd](https://www.sectoralpha.in/stocks/best-agrolife-ltd) BESTAGRO · quiet · Evidence leans up · 90% evidence 52.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.7/35 · Revenue -19.6% · Profit 100% · Operating margin change 10 points · 100% evidence Capital efficiency 10.0/25 · ROCE 5.2% (year to Mar 2026) · Operating margin 24.8% · 100% evidence Valuation 11.3/20 · P/E 10.8× · PEG n/a · 50% evidence Relative strength 6.0/20 · Strength vs its industry (price vs its 52-week average, weekly) -4.7% · Strength vs NIFTY 500 (same reading) -20.8% · 1 year -26.5% · 100% evidence · 7 of 12 weeks ahead Exact sum: 24.7 + 10 + 11.3 + 6 = 52 · What this means: Earnings are strong; relative strength in its sector is -4.7% and the one-year return is -26.5%. 10. [Meghmani Organics Ltd](https://www.sectoralpha.in/stocks/meghmani-organics-ltd) MOL · quiet · Evidence leans down · 68% evidence 49.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.9/35 · Revenue -5.2% · Profit 100% · Operating margin change 2 points · 100% evidence Capital efficiency 7.7/25 · ROCE 6.7% (year to Mar 2026) · Operating margin 10.9% · 100% evidence Valuation 10.4/20 · P/E 15.6× · PEG n/a · 15% evidence Relative strength 10.7/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) -2.3% · 1 year -23.9% · 25% evidence · 8 of 12 weeks ahead Exact sum: 20.9 + 7.7 + 10.4 + 10.7 = 49.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Excel Industries Ltd](https://www.sectoralpha.in/stocks/excel-industries-ltd) EXCELINDUS · losing its lead · Evidence leans down · 68% evidence 49.0 out of 100 Growth Capital Valuation Relative 12. [UPL Ltd](https://www.sectoralpha.in/stocks/upl-ltd) UPL · basing · Evidence leans down · 82% evidence 48.9 out of 100 Growth Capital Valuation Relative 13. [Rallis India Ltd](https://www.sectoralpha.in/stocks/rallis-india-ltd) RALLIS · quiet · Evidence leans down · 85% evidence 47.9 out of 100 Growth Capital Valuation Relative 14. [Shivalik Rasayan Ltd](https://www.sectoralpha.in/stocks/shivalik-rasayan-ltd) SHIVALIK · turning · Evidence leans down · 67% evidence 47.9 out of 100 Growth Capital Valuation Relative 15. [Bhagiradha Chemicals & Industries Ltd](https://www.sectoralpha.in/stocks/bhagiradha-chemicals-industries-ltd) BHAGCHEM · quiet · Evidence leans down · 83% evidence 47.7 out of 100 Growth Capital Valuation Relative 16. [Epigral Ltd](https://www.sectoralpha.in/stocks/epigral-ltd) EPIGRAL · quiet · Evidence leans down · 75% evidence 46.8 out of 100 Growth Capital Valuation Relative 17. [India Pesticides Ltd](https://www.sectoralpha.in/stocks/india-pesticides-ltd) IPL · quiet · Evidence leans down · 75% evidence 46.0 out of 100 Growth Capital Valuation Relative 18. [Sumitomo Chemical India Ltd](https://www.sectoralpha.in/stocks/sumitomo-chemical-india-ltd) SUMICHEM · quiet · Evidence leans down · 85% evidence 43.7 out of 100 Growth Capital Valuation Relative 19. [Insecticides India Ltd](https://www.sectoralpha.in/stocks/insecticides-india-ltd) INSECTICID · quiet · Evidence leans down · 90% evidence 42.8 out of 100 Growth Capital Valuation Relative 20. [Bharat Rasayan Ltd](https://www.sectoralpha.in/stocks/bharat-rasayan-ltd) BHARATRAS · basing · Evidence leans down · 90% evidence 42.4 out of 100 Growth Capital Valuation Relative 21. [GSP Crop Science Ltd](https://www.sectoralpha.in/stocks/gsp-crop-science-ltd) GSPCROP · quiet · Evidence leans down · 63% evidence 39.8 out of 100 Growth Capital Valuation Relative 22. [P I Industries Ltd](https://www.sectoralpha.in/stocks/p-i-industries-ltd) PIIND · quiet · Most evidence points down · 75% evidence 34.5 out of 100 Growth Capital Valuation Relative 23. [NACL Industries Ltd](https://www.sectoralpha.in/stocks/nacl-industries-ltd) NACLIND · basing · Most evidence points down · 90% evidence 32.9 out of 100 Growth Capital Valuation Relative 24. [Heranba Industries Ltd](https://www.sectoralpha.in/stocks/heranba-industries-ltd) HERANBA · quiet · Most evidence points down · 71% evidence 31.9 out of 100 Growth Capital Valuation Relative 25. [Astec Lifesciences Ltd](https://www.sectoralpha.in/stocks/astec-lifesciences-ltd) ASTEC · quiet · Most evidence points down · 71% evidence 31.3 out of 100 Growth Capital Valuation Relative Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pesticides/Agrochemicals](https://www.sectoralpha.in/sectors/pesticides-agrochemicals), all 25 compared on one page. ## Which companies are close to Sharda Cropchem in size? Sharda Cropchem is the 6th largest of 25 Pesticides/Agrochemicals companies on Sector Alpha by market value (at the 18 November 2026 close). Just above it: Sumitomo Chemical India, Bayer CropScience and Jubilant Ingrevia. Just below it: Dhanuka Agritech, Epigral and Rallis India. ### Pesticides/Agrochemicals companies close in size 1. [Sumitomo Chemical India Ltd](https://www.sectoralpha.in/stocks/sumitomo-chemical-india-ltd) ₹16,684 crore 2. [Bayer CropScience Ltd](https://www.sectoralpha.in/stocks/bayer-cropscience-ltd) ₹15,064 crore 3. [Jubilant Ingrevia Ltd](https://www.sectoralpha.in/stocks/jubilant-ingrevia-ltd) ₹9,348 crore 4. Sharda Cropchem Ltd ₹6,305 crore 5. [Dhanuka Agritech Ltd](https://www.sectoralpha.in/stocks/dhanuka-agritech-ltd) ₹4,173 crore 6. [Epigral Ltd](https://www.sectoralpha.in/stocks/epigral-ltd) ₹4,073 crore 7. [Rallis India Ltd](https://www.sectoralpha.in/stocks/rallis-india-ltd) ₹3,682 crore [All 25 Pesticides/Agrochemicals companies, largest first](https://www.sectoralpha.in/sectors/pesticides-agrochemicals#all-companies) ### Companies close in size in other industries 1. [Kirloskar Ferrous Industries Ltd](https://www.sectoralpha.in/stocks/kirloskar-ferrous-industries-ltd) ₹6,335 crore · Steel - Pig Iron 2. [Birla Corporation Ltd](https://www.sectoralpha.in/stocks/birla-corporation-ltd) ₹6,320 crore · Cement 3. Sharda Cropchem Ltd ₹6,305 crore 4. [Shrem InvIT](https://www.sectoralpha.in/stocks/shrem-invit) ₹6,292 crore · Infrastructure Investment Trusts 5. [Dilip Buildcon Ltd](https://www.sectoralpha.in/stocks/dilip-buildcon-ltd) ₹6,259 crore · EPC ## What else do people ask about Sharda Cropchem? ### What is Sharda Cropchem's share price today? Sharda Cropchem Ltd's share price is ₹698.75, −12.6% over the past year. The whole company is worth ₹6,309 Cr on the market. In the last 52 weeks it traded between ₹643 to ₹1,256; today it is 9% of the way up from the low, 15.5% below its 200-day average (as of 18 November 2026). ### What were Sharda Cropchem's latest quarterly results? Sharda Cropchem Ltd reported revenue of ₹1,052 Cr and net profit of ₹92.0 Cr for the Sep 2026 quarter. Revenue rose 13.2% and profit rose 24.3% compared with a year earlier. Earnings per share were ₹10.17. The operating margin was 15.6%, 1.3 percentage points higher than a year earlier (as of 18 November 2026). ### What is Sharda Cropchem's market cap? Sharda Cropchem Ltd's market capitalisation is ₹6,309 Cr at a share price of ₹698.75. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 18 November 2026). ### What is Sharda Cropchem's P/E ratio? Sharda Cropchem Ltd's P/E is 9.8×, higher than 2% of its own last 11 years. Its usual level (the middle reading) is 16.8×. This compares the price with the company's own past; it is not a view on what the shares are worth (as of 18 November 2026). ### How is Sharda Cropchem valued against its own history? Against its own history, Sharda Cropchem Ltd's valuation is low: its P/E of 9.8× has been lower only 2% of the time in 11 years (usual level 16.8×). This compares the price with the company's own past; it is not a view on what the shares are worth or where the price goes next (as of 18 November 2026). ### How is Sharda Cropchem performing? Sharda Cropchem Ltd's share price has been falling for 18 weeks. In its latest quarter, revenue rose 13.2% and profit rose 24.3% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 35 weeks running (as of 18 November 2026). ### Will Sharda Cropchem's share price go up? This page does not forecast Sharda Cropchem Ltd's share price. What it shows instead: the share price is ₹698.75, and it has been falling for 18 weeks. Its P/E of 9.8× is higher than 2% of its own last 11 years (as of 18 November 2026). ### Who owns Sharda Cropchem? Promoters own 74.8% of Sharda Cropchem Ltd, foreign institutions 3.3%, domestic institutions 9.2% and the public 12.7% (latest quarter). The biggest change over the last two years: Domestic institutions cut their stake by 3.5 percentage points over 8 quarters (as of 18 November 2026). ### Does Sharda Cropchem have too much debt? No, Sharda Cropchem Ltd has little debt: its debt is 0.00× its equity, and its operating profit is 50 times its interest bill. FY26 borrowings were ₹0.0 Cr against equity of ₹3,136 Cr. So the returns on this page come from the business, not borrowed money (as of 18 November 2026). ### Where is Sharda Cropchem in its business cycle? Sharda Cropchem Ltd's FY26 operating margin was 20.1%, against a 13-year range of 9.6% to 23.2%. The latest quarter was 15.6%, the middle of its own range, neither a peak nor a low. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 18 November 2026). ### What could break the Sharda Cropchem story? The main question: yearly earnings per share moved +123.7% while the share price moved −12.6%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 18 November 2026). ### Is Sharda Cropchem a stock worth studying right now? What the numbers show: Sharda Cropchem Ltd's earnings have grown faster than its share price. Earnings per share grew +123.7% in a year while the price moved −12.6%. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 18 November 2026). ### Is there a Sharda Cropchem share price forecast for 2026? What management itself guided: FY27 revenue growth 10-15%. ## Lists - Dividend stocks: https://www.sectoralpha.in/dividend-stocks-india This is research, not advice. We’re not SEBI-registered.